Avinger Inc. (AVGR) shares soared 20.36% in after-hours on Friday, January 14, 2022, and closed the weekly trading at $0.37. However, in the regular trading session of Friday, AVGR’s stock lost 0.57% to close Friday’s session at $0.31. AVGR shares have fallen 78.78% over the last 12 months, and they have moved down 32.20% in the past week. Over the past three months, the stock has lost 59.99%, while over the past six months, it has declined 68.16%.
Let’s have a brief discussion about its recent news and developments.
AVGR closed its common stock offer
On January 14, 2022, Avinger, Inc. (AVGR) closed its previously announced registered direct offering of an aggregate of 7,600 shares of Series D convertible preferred stock and warrants to purchase up to an aggregate of 16,150,000 shares of common stock to certain institutional investors.
The company will get gross proceeds of $7.6 million and shares of Preferred Stock have a stated value of $1,000 per share and are convertible into an aggregate of 19,000,000 shares of common stock at a conversion price of $0.40 per share. The warrants will expire five years following such an initial exercise date.
FDA clearance for AVGR Lightbox 3 imaging console
On January 11, 2022, Avinger, Inc. (AVGR), received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console.
The company is looking to launch Lightbox 3 in the United States early in the first quarter of 2022. Lightbox 3 presents a significant reduction in size, weight, and cost compared to the existing platform with more advanced features such as an advanced solid-state laser for enhanced high-definition OCT imaging, a more powerful computing platform, and a redesigned software system with a highly intuitive user interface that emphasizes efficiency and ease-of-use.
AVGR received FDA clearance for Pantheris
On November 17, 2021, Avinger, Inc. (AVGR), received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for a new clinical indication for the Pantheris image-guided atherectomy system. This clearance allows the company to directly market Pantheris for the treatment of in-stent restenosis (ISR) in the lower extremity arteries.
AVGR latest financial results
On November 11, 2021, Avinger, Inc. (AVGR), announced results for the third quarter ended September 30, 2021.
Q3 2021 financial highlights
- AVGR reported revenue of $2.4 million for the third quarter of 2021 compared to $ for the third quarter of 2020.
- In Q3 2021, the gross margin was 34% which was the same in Q3 2020.
- Total operating expenses were $5.3 million, compared with $4.9 million in the third quarter of 2020.
- It suffered a net loss of $6.0 million in Q3 2021, compared with $5.5 million in the third quarter of 2020.
- Adjusted EBITDA was a loss of $4.1 million in Q3 2021, compared with a loss of $3.5 million in Q3 2020.
AVGR stock performed well in the after-hours on Friday after it announced to close the pricing of its common stock offer. We hope that it will continue to its momentum after the long weekend as well.